Piramal Pharma Limited (NSE:PPLPHARMA)

Market Cap	266.14B
Revenue (ttm)	91.51B
Net Income (ttm)	911.30M
Shares Out	1.33B
EPS (ttm)	0.68
PE Ratio	294.44
Forward PE	139.91
Dividend	0.14 (0.07%)
Ex-Dividend Date	Jul 16, 2025

Volume	2,574,122
Average Volume	4,066,379
Open	200.92
Previous Close	200.22
Day's Range	197.50 - 201.83
52-Week Range	145.25 - 307.90
Beta	0.08
RSI	38.64
Earnings Date	Jul 28, 2025

About Piramal Pharma

Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which off...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2020
• Employees: 6,719
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: PPLPHARMA

Financial Performance

In 2024, Piramal Pharma's revenue was 91.51 billion, an increase of 11.99% compared to the previous year's 81.71 billion. Earnings were 911.30 million, an increase of 411.39%.